Evidence map›Paper›PMID 12200704›Full record

ArticleLeukemia2002

BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5' regulatory region of the BCL-6 gene.

I S Lossos, R Warnke, R Levy

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Transformation of follicular lymphoma.Best practice & research. Clinical haematology · 2011
    Review
  4. Article
  5. The human BCL6 transgene promotes the development of lymphomas in the mouse.Proceedings of the National Academy of Sciences of the United States of America · 2004
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

I S LossosDivision of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA 94305-5306, USA.
R Warnke
R Levy
Stanford Medicine · US

Funding

TRIGGERING CELL DEATH IN B CELL LYMPHOMAP01CA034233 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W · 1985 to 2010
$19.5M
ANTIIDIOTYPE THERAPY OF HUMAN B CELL MALIGNANCYR37CA033399 · NCI · STANFORD UNIVERSITY · PI LEVY, RONALD · 1988 to 2007
$4.5M
HUMAN ANTITUMOR THERAPY WITH MONOCLONAL ANTIBODIESR01CA033399 · NCI · STANFORD UNIVERSITY · PI LEVY, RONALD · 1985 to 1998
–
NCI NIH HHS CA33399NCI NIH HHS CA34233
6 · The paper itself

Abstract

Follicle center lymphoma (FCL) is an indolent low-grade B cell non-Hodgkin's lymphoma (NHL) that frequently transforms to aggressive diffuse large B cell lymphoma (DLBCL). Histological transformation of FCL is commonly associated with accumulation of secondary genetic alterations. The BCL-6 gene is commonly implicated in the pathogenesis of DLBCL and its expression may be altered by clonal rearrangements and somatic point mutations in its 5' non-translated regulatory region. Recently, somatic mutations of the BCL-6 gene were associated with the transformation process. Here, we examined BCL-6 mRNA expression and BCL-6 mutations in paired biopsies from the same patients obtained at the time of FCL diagnosis and after transformation. BCL-6 mRNA expression markedly increased upon transformation (1.9- to 4.8-fold) in three cases, remained unchanged in one case and decreased compared to the diagnosis FCL specimens in four cases. The three specimens that demonstrated an increase in the BCL-6 mRNA expression upon transformation harbored BCL-6 gene mutations in the 5' region of the first intron that overlapped with the previously reported negative regulatory region of the gene. Accumulation of new mutations in this region was not observed in DLBCL biopsies in which the BCL-6 mRNA expression did not increase. The present study demonstrates that although BCL-6 gene mutations do accumulate during the transformation process and, depending on their location within the first intron, may deregulate BCL-6 mRNA expression, increase in BCL-6 mRNA expression is not uniformly required for transformation from FCL to DLBCL.

Indexed as

Mutation5' Untranslated RegionsCell Transformation, NeoplasticDNA-Binding ProteinsDNA PrimersHumansImmunoenzyme TechniquesLymphoma, B-CellLymphoma, FollicularLymphoma, Large B-Cell, DiffusePolymerase Chain ReactionProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-6RNA, MessengerRNA, NeoplasmTranscription Factors5' Untranslated RegionsDNA-Binding ProteinsDNA PrimersProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-6RNA, MessengerRNA, NeoplasmTranscription Factors

Identifiers

PMID12200704
OpenAlexW2314416506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.